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Background: Somatic mutations in the epidermal growth factor re-
ceptor (EGFR) gene are a predictor of response to treatment with EGFR
tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung
cancer (NSCLC). However, mechanisms of de novo resistance to these
drugs in patients harboring EGFR mutations have remained unclear.
We examined whether the mutational status of KRAS might be associ-
ated with primary resistance to EGFR-TKIs in EGFRmutation-positive
patients with NSCLC.
Methods: Forty patients with NSCLC with EGFR mutations who
were treated with gefitinib or erlotinib and had archival tissue
specimens available were enrolled in the study. KRAS mutations
were analyzed by direct sequencing.
Results: Three (7.5%) of the 40 patients had progressive disease,
and two (67%) of these three individuals had both KRAS and EGFR
mutations.
Conclusions: Our results suggest that KRAS mutation is a negative
predictor of response to EGFR-TKIs in EGFR mutation-positive
patients with NSCLC.
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(J Thorac Oncol. 2010;5: 399–400)
A total of 40 patients with non-small cell lung cancer(NSCLC) harboring epidermal growth factor receptor
(EGFR) mutations were treated with gefitinib (n  36) or
erlotinib (n  4) between September 2002 and January 2009,
and three patients exhibited resistance to EGFR-tyrosine kinase
inhibitor (TKIs). (i) Case 1 was a 63-year-old man who had
never smoked and was diagnosed with lung adenocarcinoma of
stage IV. Molecular screening identified a deletion mutation in
exon 19 of EGFR, and he had received gefitinib as the second-
line therapy. Although he tolerated gefitinib well, the primary
lung lesion showed slow but steady growth, and he was removed
from therapy because of his progressive disease (PD) at day 58
(Figure 1A). (ii) Case 2 was a 69-year-old man who had never
smoked, had adenocarcinoma of stage IIIB, harbored a deletion
in exon 19 of EGFR, and was treated with erlotinib as the
third-line therapy. A chest computed tomography scan on day 28
revealed enlargement of the primary lung lesion, and the case
was subsequently classified as PD (Figure 1B). (iii) Case 3 was
a 52-year-old man who was a current smoker, had lung adeno-
carcinoma of stage IV with left adrenal metastasis, harbored a
deletion in exon 19 of EGFR, and received erlotinib as the
fourth-line therapy. Chest computed tomography on day 32
showed enlargement of the left adrenal metastasis, resulting in a
classification of PD (Figure 1C). Thus, these clinical data dem-
onstrated the existence of de novo resistance to EGFR-TKIs in
EGFR mutation-positive patients. We examined the mutational
status of KRAS in the three patients who showed PD as their best
response. An amino acid substitution at codon 12 (G12D) of
KRAS was identified in two of these three patients (Figure 1D–F).
DISCUSSION
Somatic mutations of the EGFR gene are associated with
an increased response to EGFR-TKI in patients with NSCLC.
Several prospective clinical trials of EGFR-TKI treatment for
patients with NSCLC with EGFR mutations have subsequently
revealed radiographic response rates of 55 to 91%. It remains of
clinical concern, however, that a small proportion of patients
with NSCLC with EGFR mutations show de novo resistance to
EGFR-TKIs and that molecular markers to predict a lack of
response to these drugs remain to be identified. We have now
examined KRAS mutation status in EGFR mutation-positive
patients with NSCLC treated with EGFR-TKIs and found a high
incidence of concomitant KRASmutation in individuals who did
not respond to these drugs. Our results indicate that KRAS
mutation may be clinically useful as a negative predictive
marker of sensitivity to EGFR-TKIs in patients with NSCLC
with EGFR mutations. Previous studies have also shown that
KRASmutations are associated with resistance to EGFR-TKIs in
patients with NSCLC and that EGFR and KRAS mutations
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appear to be mutually exclusive in such patients,1–3 suggesting
that KRAS mutations are predictors of unresponsiveness to
EGFR-TKIs in patients with NSCLCwith wild-type EGFR. The
mutual exclusivity of EGFR and KRAS mutations combined
with their prevalence patterns in lung adenocarcinoma, with
KRAS mutations being preferentially found in smokers and
EGFR mutations in nonsmokers, suggests that the mutations in
these two genes might arise through different pathogenic path-
ways. Conversely, some studies have shown that KRAS muta-
tions do sometimes coexist with EGFR mutations in patients
with NSCLC.4,5 The extent of coexistence of EGFR and KRAS
mutations in NSCLC thus remains unclear, in large part as a
result of the low frequency of KRAS mutations, and the clinical
relevance of KRAS mutations in EGFR mutation-positive pa-
tients has remained unknown. We have now shown that patients
with NSCLC harboring EGFR mutations who exhibit de novo
resistance to EGFR-TKIs have a high incidence of KRAS mu-
tation, suggesting that the presence of KRAS mutations might
provide a basis for the identification of EGFR mutation-positive
patients who are unlikely to benefit from EGFR-TKI treatment.
Our clinical findings are consistent with preclinical data showing
that forced expression of mutant KRAS in PC-9 human NSCLC
cells, which harbor an activating mutation of EGFR, resulted in
a reduction in the sensitivity of these cells to gefitinib.6 Gefitinib
shuts down both PI3K-AKT and RAS-RAF-MEK-ERK signal-
ing pathways in PC-9 cells; however, expression of the KRAS
mutant resulted in constitutive activation of these signaling
pathways in a manner independent of EGFR activation, leading
to continued cell growth and survival.
In July 2009, gefitinib received a license from the Euro-
pean Medicines Agency for all lines of therapy in patients with
locally advanced or metastatic NSCLC positive for activating
mutations of EGFR. More patients with EGFR mutation-posi-
tive tumors will thus now receive EGFR-TKIs. Our present
results suggest that EGFR-TKIs should not be given routinely to
patients harboring concomitant KRAS and EGFR mutations. In
the event that such patients do receive treatment with EGFR-
TKIs, they should be followed up after a short interval to obtain
early evidence of possible tumor progression.
KRASmutations cannot account for all cases of de novo
resistance to EGFR-TKIs in EGFR mutation-positive patients
with NSCLC. A recent study showed that loss of PTEN
contributes to erlotinib resistance in an EGFR mutation-
positive NSCLC cell line.7 Loss of PTEN resulted in partial
uncoupling of the mutant EGFR from downstream signaling
and further activated the receptor, leading to erlotinib resis-
tance. Both homozygous deletion of PTEN and EGFR muta-
tion were detected in one of 24 clinical specimens of NSCLC
with EGFR mutations, although the efficacy of EGFR-TKIs
was not evaluated in the corresponding patient.
In conclusion, our results suggest that KRAS mutation
status should be assessed before initiation of EGFR-TKI
treatment in EGFR mutation-positive patients with NSCLC,
allowing enrichment of the population of such patients who
are likely to prove responsive to the treatment.
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FIGURE 1. Clinical and molecular
characteristics of patients with non-
small cell lung cancer (NSCLC) who
showed de novo resistance to epider-
mal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs). A–C,
Computed tomography (CT) images
obtained before and after EGFR-TKI
treatment for cases 1 to 3, respec-
tively. D–F, Sequence chromato-
graphs of KRAS mutation status deter-
mined with tumor tissue isolated
before EGFR-TKI treatment for cases 1
to 3, respectively. Arrows indicate the
mutated nucleotide (G3A) in codon
12 for cases 2 and 3.
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